TY - JOUR
T1 - CANTO-RT
T2 - Skin toxicities evaluation of a multicentre large prospective cohort of irradiated patients for early-stage breast cancer
AU - Allali, Sofiane
AU - Carton, Matthieu
AU - Sarrade, Thomas
AU - Querel, Ophélie
AU - Jacquet, Alexandra
AU - Rivera, Sofia
AU - Ghannam, Youssef
AU - Peignaux, Karine
AU - Guilbert, Philippe
AU - Chara-Brunaud, Claire
AU - Blanchecotte, Julien
AU - Pasquier, David
AU - Racadot, Séverine
AU - Bourgier, Céline
AU - Labib, Alain
AU - Geffrelot, Julien
AU - Benyoucef, Ahmed
AU - Paris, François
AU - Cottu, Paul
AU - André, Fabrice
AU - Kirova, Youlia
N1 - Publisher Copyright:
© 2022 UICC.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Skin damage is the most common and most important toxicity during and after radiation therapy (RT). Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients irradiated for an early breast cancer. CANTO is a prospective clinical cohort study of 10 150 patients with stage I-III BC treated from 2012 to 2017 in 26 cancer centres. In our study, we used CANTO-RT, a subcohort of CANTO, including 3480 patients who received RT. We are focus on specific skin toxicities: erythema, fibrosis, telangiectasia and cutaneous pigmentation. The prevalence of toxicities of interest varied over time, so at baseline for early toxicity Month (M) 0-3-6, 41.1% of patients had erythema while 24.8% of patients had fibrosis. At M12 and M36, the prevalence of erythema decreased, respectively, while fibrosis remains stable. The prevalence of telangiectasia increases from 1% to 7.1% from M0-3-6 to M36. After adjustments, we showed an association between the occurrence of skin erythema and obesity; the type of surgery; the presence of axillary dissection; the use of taxane-based CT and the 3D vs IMRT irradiation technique. Regarding fibrosis, an association is found, at M0-3-6, with age at diagnosis, obesity, tobacco and the use of boost. Only obesity and the type of surgery received by the patient remained statistically significant at M12 and M36. In our study we identified several risk factors for acute and late skin reactions. The use of a boost was mainly related to the occurrence of fibrosis while the use of IMRT-type technique decreased the occurrence of skin erythema.
AB - Skin damage is the most common and most important toxicity during and after radiation therapy (RT). Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients irradiated for an early breast cancer. CANTO is a prospective clinical cohort study of 10 150 patients with stage I-III BC treated from 2012 to 2017 in 26 cancer centres. In our study, we used CANTO-RT, a subcohort of CANTO, including 3480 patients who received RT. We are focus on specific skin toxicities: erythema, fibrosis, telangiectasia and cutaneous pigmentation. The prevalence of toxicities of interest varied over time, so at baseline for early toxicity Month (M) 0-3-6, 41.1% of patients had erythema while 24.8% of patients had fibrosis. At M12 and M36, the prevalence of erythema decreased, respectively, while fibrosis remains stable. The prevalence of telangiectasia increases from 1% to 7.1% from M0-3-6 to M36. After adjustments, we showed an association between the occurrence of skin erythema and obesity; the type of surgery; the presence of axillary dissection; the use of taxane-based CT and the 3D vs IMRT irradiation technique. Regarding fibrosis, an association is found, at M0-3-6, with age at diagnosis, obesity, tobacco and the use of boost. Only obesity and the type of surgery received by the patient remained statistically significant at M12 and M36. In our study we identified several risk factors for acute and late skin reactions. The use of a boost was mainly related to the occurrence of fibrosis while the use of IMRT-type technique decreased the occurrence of skin erythema.
KW - breast cancer
KW - erythema
KW - fibrosis
KW - radiotherapy
KW - skin toxicity
UR - http://www.scopus.com/inward/record.url?scp=85133053573&partnerID=8YFLogxK
U2 - 10.1002/ijc.34057
DO - 10.1002/ijc.34057
M3 - Article
C2 - 35489021
AN - SCOPUS:85133053573
SN - 0020-7136
VL - 151
SP - 1098
EP - 1108
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 7
ER -